RBC
TXG icon

Romano Brothers & Co’s 10x Genomics TXG Stock Holding History

Romano Brothers & Co’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-73
Closed -$2.66K – 928
2022
Q4 		$2.66K Buy
+73
New +$2.39K ﹤0.01% 903

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Romano Brothers & Co's TXG Position: Q1 2023 in Review

Romano Brothers & Co sold out of 10x Genomics (TXG) in Q1 2023, closing a stake of 73 shares — an estimated $2.66K sold.

Romano Brothers & Co first reported a position in TXG in Q4 2022 and held it in 1 quarter. The position peaked at $2.66K in Q4 2022. 258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

  • Romano Brothers & Co reported no remaining 10x Genomics position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 73 10x Genomics shares in Q1 2023, an estimated $2.66K.
  • Romano Brothers & Co first reported a position in 10x Genomics in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's 10x Genomics position peaked at $2.66K in Q4 2022.
  • 258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.